The review, conducted by Hanmo Yin and Nasrudin Subhi of Universiti Kebangsaan Malaysia together with Rozainee Khairudin of Taylor’s University, set out to answer a deceptively simple question: do depression and socioeconomic position reliably change how people respond to unfair offers? The question matters because both factors have been repeatedly implicated in studies of economic behavior. Depression is known to alter emotional processing, reward sensitivity, and social cognition, while socioeconomic status shapes everything from risk tolerance to long-term planning. If either factor systematically distorts fairness-related decision-making, the implications could reach into mental health practice, economic policy, and our understanding of social inequality itself.

To investigate, the team searched PubMed, PsycINFO, Web of Science, and Google Scholar for peer-reviewed articles published up to June 2026. They applied strict eligibility criteria: studies had to use the Ultimatum Game or a closely related paradigm and had to examine either depression or socioeconomic status in relation to the rejection of unfair offers. Rejection rates served as the behavioral index throughout, because refusing a low offer is widely interpreted as costly punishment—the participant sacrifices real money to penalize a partner perceived as unfair. After screening and appraisal using PRISMA reporting standards and the Joanna Briggs Institute critical appraisal checklist, eighteen studies met the inclusion criteria: eleven examining depression alone, six examining socioeconomic status alone, and a single study addressing both factors simultaneously.

The narrative synthesis of these eighteen studies revealed a strikingly inconsistent picture. Among the depression-focused studies, some reported that depressed participants rejected unfair offers more often than healthy controls, consistent with theories that heightened negative emotion or impaired emotion regulation amplifies reactions to unfairness. Others found the opposite pattern, with depression linked to lower rejection rates, perhaps reflecting diminished sensitivity to social reward or a reduced willingness to engage in costly punishment. Still others detected no significant association at all. The socioeconomic status literature told an equally fragmented story, with income, education, occupation, and subjective social standing producing divergent results depending on how each was measured and which task variant was deployed.

To move beyond narrative impressions, the researchers conducted separate random-effects meta-analyses for the depression-related and socioeconomic-status-related effects. The pooled estimates for both factors were non-significant, meaning that across studies, neither depression nor socioeconomic status showed a reliable overall effect on unfair-offer rejection. In the depression meta-analysis, heterogeneity—the statistical variability among study effects—was significant, signaling that the true effect likely differs across populations, clinical profiles, and experimental conditions. In the socioeconomic status analysis, the heterogeneity index was high even though the Q-test for heterogeneity did not reach significance, a pattern the authors attribute to limited statistical power given the small number of included studies.

These findings strike a direct blow against a seductive simplification: the idea that depression uniformly makes people more vindictive toward unfairness, or that poverty or low social standing makes people either more compliant or more rebellious in economic negotiations. The evidence, the authors conclude, supports no such uniform conclusion. Instead, the effects of both depression and socioeconomic status on fairness-related decision-making appear heterogeneous and deeply context-dependent. What happens in the brain of a person with major depressive disorder rejecting a lowball offer may depend on symptom severity, current clinical status, medication, the size of the stakes, and the cultural framing of the task. Likewise, the behavioral signature of socioeconomic disadvantage may shift depending on whether status is measured by income, educational attainment, occupational prestige, or a person’s subjective sense of where they stand on the social ladder.

The technical details of the meta-analytic approach reinforce the credibility of the null result. The authors used restricted maximum likelihood estimation, a standard method for fitting random-effects models that accommodates between-study variability, and followed the PRISMA 2020 guidelines for transparent reporting, with supplementary materials including the full checklist, critical appraisal forms, extraction data, and the R code used for the analyses. This open methodological scaffolding allows other researchers to reproduce the pooled estimates, test alternative models, and identify precisely where the heterogeneity originates. In a field where small samples and task variations frequently produce contradictory findings, such transparency is itself a form of scientific progress.

Why might the expected effects fail to materialize at the pooled level? The review points to several plausible cognitive-affective mechanisms. Rejection of an unfair offer is thought to emerge from an interplay between fairness appraisal—cognitive judgments about whether a split violates social norms—and emotional responses to unfairness, such as anger or resentment. Depression could plausibly act on either side of this ledger: it may blunt the emotional sting of unfairness through anhedonia and reduced reward responsiveness, or it may intensify negative interpretation biases that make ambiguous offers feel hostile. Which direction dominates could depend on the severity of symptoms, the phase of the illness, or comorbid anxiety. Similarly, socioeconomic status could shape rejection behavior through long-term exposure to scarcity, which sometimes promotes acceptance of uneven deals out of necessity, and sometimes fosters heightened sensitivity to being exploited. The single study that examined depression and socioeconomic status together underscores how little direct empirical work exists on their joint influence—a gap the authors identify as a priority for future research.

The methodological critique embedded in the review is equally consequential. Studies in this literature vary widely in how they operationalize both the clinical and the socioeconomic constructs, and in how they configure the Ultimatum Game itself. Stake sizes, offer distributions, partner identity, and whether offers come from humans or computers all modulate rejection behavior. Without standardized paradigms and clearly defined clinical and socioeconomic measures, meta-analytic pools inevitably mix apples and oranges, inflating heterogeneity and obscuring genuine effects. The authors recommend that future studies adopt standard behavioral Ultimatum Game protocols and precise, validated measurements, and that they explicitly test interaction effects between depression and socioeconomic status rather than treating the two as separate, competing predictors.

The broader lesson resonates well beyond the economics laboratory. Public discourse often leans on simple narratives in which mental illness or poverty determines behavior in predictable ways. This meta-analysis is a reminder that human social decision-making resists such neat categorization. The inclination to punish unfairness emerges from a dynamic negotiation between emotion, cognition, context, and identity—and no single demographic or clinical variable appears to command it. For researchers, the null pooled effects are not an endpoint but an invitation: to design better-powered, better-specified studies that can map the conditions under which depression and social position do, in fact, bend our sense of fairness. For the rest of us, the findings counsel humility about how much we can infer about a person’s choices from a diagnosis or a paycheck alone.

Subject of Research: The impact of depression and socioeconomic status on fairness-related socioeconomic decision-making.

Article Title: What is the impact of depression and socioeconomic status on socioeconomic decision-making: a systematic review and meta-analysis

Article References: What is the impact of depression and socioeconomic status on socioeconomic decision-making: a systematic review and meta-analysis. (n.d.). https://doi.org/10.1186/s40359-026-05443-z

Image Credits: AI Generated

DOI: 10.1186/s40359-026-05443-z

Keywords: depression, socioeconomic status, Ultimatum Game, decision-making, meta-analysis, systematic review, fairness, behavioral economics, mental health, social inequality, impact, socioeconomic

The research, published in the International Journal of Obesity, exploits one of the distinctive strengths of the Nordic research infrastructure. In Finland, comprehensive national registers record prescription drug purchases, healthcare utilization, education, income, employment status, family structure and place of residence for virtually the entire population. By linking these registers at the individual level, researchers can assemble an exceptionally complete picture of medication use across society, free from the recall bias, volunteer bias and loss to follow-up that plague conventional surveys. This makes register studies of this kind uniquely suited to detecting systematic patterns in who accesses treatment and who is left behind.

The scale of the analyzed population matters for the credibility of the findings. With more than a quarter of a million Finnish adults in the study cohort, even relatively small differences in medication uptake between social groups become statistically detectable, and the results are far less likely to be distorted by random variation. Small clinical studies, which typically follow a few hundred patients at specialized obesity clinics, capture only the narrow slice of people who reach tertiary care. A register study, by contrast, observes the full pipeline, from primary care prescriptions through pharmacy dispensing records, and therefore reflects everyday clinical practice rather than the highly selected environment of academic weight-management centers.

Why should the distribution of anti-obesity medication be socially patterned at all? In principle, obesity is not distributed evenly across society in the first place. Decades of epidemiological research, particularly in high-income countries, have consistently shown that obesity prevalence is inversely associated with socioeconomic position: people with lower levels of education and income carry a higher burden of obesity in many populations. If treatment followed need, one would therefore expect anti-obesity medications to be prescribed at least as often, and possibly more often, to people from disadvantaged backgrounds. Whether that is actually the case is the empirical question at the heart of the Finnish register study.

The answer is far from guaranteed, because multiple forces pull access in different directions. On one side sit barriers that tend to concentrate among socioeconomically disadvantaged groups: out-of-pocket medication costs, the ability to navigate healthcare systems, geographic distance from providers who prescribe these drugs, and the time and flexibility required for the frequent follow-up appointments that anti-obesity pharmacotherapy typically demands. On the other side sit factors that may favor advantaged groups or, in some contexts, disadvantage them differently, including physician prescribing preferences, awareness of and demand for newer therapies, and insurance or reimbursement structures that determine how much of the medication price each patient must shoulder.

Anti-obesity pharmacotherapy is also a moving target, and this temporal dimension shapes any register analysis. Older agents, such as orlistat, which acts by inhibiting intestinal fat absorption, and older noradrenergic appetite suppressants, have been joined in recent years by glucagon-like peptide-1 receptor agonists originally developed for type 2 diabetes and subsequently approved for chronic weight management. These newer agents have demonstrated substantially greater average weight loss in randomized trials, but they are also expensive, administered by weekly injection, and often subject to reimbursement restrictions and supply shortages. The social profile of who uses anti-obesity medications is therefore not static; it evolves as the drug landscape, the regulatory environment and public attention to obesity treatment change.

Register data allow researchers to trace these patterns across the entire adult population, stratifying medication use by sex, age, education, income, employment and family circumstances. This multidimensional approach is important because socioeconomic position is not a single variable. Education captures early-life and cognitive resources, income captures current material means, and employment captures attachment to institutions that shape healthcare access. Different dimensions can point in different directions: for instance, medication use might rise with income while showing a different gradient with age or family status. Only a sufficiently large and richly linked dataset can disentangle these overlapping gradients, which is precisely the analytical opportunity afforded by the Finnish registers.

Finland offers a particularly informative setting for this kind of inquiry. Like its Nordic neighbors, it provides tax-funded healthcare to all residents, which softens but does not eliminate the role of purchasing power in treatment access. Prescription medications in Finland are subject to a tiered reimbursement system administered through the national health insurance scheme, and anti-obesity drugs have historically faced strict limits on reimbursement, leaving many patients to pay substantial costs out of pocket. Primary health centers deliver most routine care, while referral pathways govern access to specialized obesity treatment. How these institutional arrangements translate into equitable or inequitable access is exactly the sort of question that register linkage can address with a precision unattainable in most other countries.

The stakes of the question extend well beyond Finland. Health systems worldwide are confronting an unprecedented surge in demand for anti-obesity medications, driven both by rising obesity prevalence and by the demonstrated efficacy of newer agents. Supply constraints, insurance coverage debates and clinical guideline decisions all hinge on assumptions about who benefits from and who deserves access to these therapies. If real-world uptake is systematically skewed by education, income or demography, then the newest and most effective obesity treatments risk widening existing health inequalities rather than narrowing them, echoing patterns previously documented for bariatric surgery, where uptake has often been concentrated among groups that are urban, insured and socioeconomically advantaged despite obesity being more prevalent elsewhere.

For researchers, the Finnish register study of 282,307 adults provides a template for monitoring this emerging therapeutic landscape systematically. For clinicians and policymakers, it underscores that the effectiveness of anti-obesity medications in populations depends not only on their performance in randomized trials but on whether the people who need them most actually receive them. As new agents enter the market and reimbursement policies are revised, continued surveillance of sociodemographic and socioeconomic gradients in medication use will be essential to ensure that the pharmacological revolution in obesity treatment reaches all segments of society rather than only those already best positioned to seize it.

Subject of Research: Sociodemographic and socioeconomic differences in anti-obesity medication use among Finnish adults

Article Title: Sociodemographic and socioeconomic differences in the use of anti-obesity medications: a register study among 282,307 Finnish adults

Article References: Valkonen, J., Svärd, A. C., Roos, E., Joki, A., Kouvonen, A., & Lallukka, T. (2026). Sociodemographic and socioeconomic differences in the use of anti-obesity medications: a register study among 282,307 Finnish adults. International Journal of Obesity. https://doi.org/10.1038/s41366-026-02213-0

Image Credits: AI Generated

DOI: 10.1038/s41366-026-02213-0

Keywords: anti-obesity medications, socioeconomic differences, register study, Finland, obesity treatment, health inequality, pharmacotherapy, prescription drugs, obesity epidemiology, healthcare access, Sociodemographic, socioeconomic